NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

Can-Fite BioPharma Ltd. (CANF) Stock Analysis

Can-Fite BioPharma Ltd. (CANF) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

CANF

$1.89

−$0.00 (−0.02%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CANF with… →

CANF Key Statistics

As of Oct 21, 2026
Trading
Open
$1.91
Previous Close
$1.89
Day's Range
1.83–1.92
52-Week Range
1.90–12.40
Volume
11.16K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.02
Valuation
Market Cap
$5.91M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.60
EPS (ttm)Profit attributable to each share over the last twelve months.
−13.23
Financials (FY)
Revenue (FY)
$405.00K−39.91%
Net Income (FY)
−$9.83M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.03M
1-Year Return
−81.47%
Dividend and dates
Avg Volume
386.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CANF closed at $1.89, −81.47% over 1 year.

Can-Fite BioPharma Ltd. (CANF) has a market capitalization of $5.91M.

In fiscal 2025, CANF reported revenue of $405.00K.

CANF Stock Return by Calendar Year

Can-Fite BioPharma Ltd. (CANF) 10-year return: what $10,000 became

1 year
$10,000 $1,853
−81.47%
5 years
$10,000 $60
−99.40%
10 years
$10,000 $3
−99.97%

If you had invested $10,000 in Can-Fite BioPharma Ltd. (CANF) 10 years ago, at the close on October 21, 2016, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −56.12% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−52.76%
2025−87.73%
2024−25.91%
2023−63.93%
2022−52.71%
2021−27.53%
2020−46.06%
2019−82.54%
2018−14.86%
2017−37.82%
2016 (partial year)+8.68%

As of October 21, 2026.

CANF Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$405.00K−$9.83M−2,426.7%
2024$674.00K−$7.88M−1,169.1%
2023$743.00K−$7.63M−1,027.5%
2022$810.00K−$10.17M−1,255.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$405.00K—−$9.95M−$9.83M−2,426.7%
2024$674.00K—−$8.13M−$7.88M−1,169.1%
2023$743.00K—−$8.20M−$7.63M−1,027.5%
2022$810.00K—−$10.10M−$10.17M−1,255.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CANF Valuation vs Biotechnology Median

Median of 608 stocks
MetricCANFBiotechnology medianvs median
P/S ratio14.6013.3010% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Can-Fite BioPharma Ltd. (CANF) carries a market capitalisation of $5.91M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 5.

The 52-week range on file runs from $1.90 to $12.40. CANF last closed at $1.89 on October 21, 2026. That is $0.00 (−0.02%) against the previous close.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $405.00K. That is −39.91% against the prior fiscal year, when revenue was $674.00K. The same year closed with a net loss of $9.83M. Trailing earnings per share are −13.23.

Across the 4 fiscal years on file, revenue moves from $810.00K in 2022 to $405.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 14.6. On price-to-sales that is 9.76% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −81.47%. Across 10 years the annualized return works out at −56.12%. Beta against the wider market is reported at −0.02. Daily returns over the trailing 10 years annualize to a volatility of 84.23%.

Growth & Income

The record shows no dividend for CANF.

2026 is still running; the total return is −52.76% year to date. Across the complete calendar years on file, 2018 returned −14.86% and 2025 returned −87.73%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Can-Fite BioPharma Ltd. (CANF) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Can-Fite BioPharma Ltd. CANF $5.91M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Can-Fite BioPharma Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Visit website →